SETD2 and central nervous system cancer: The frequency of SETD2 mutation (24%, 4/17) in DCGs was significantly higher than those in previous large-scale genetic analyses of adult gliomas, which showed a SETD2 mutation rate of 1.7% in GBM (5/292, p = 0.0007) and 2.1% in lower-grade glioma (3/283, p = 0.0002) [6, 8].